Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Theravance Biopharma, Inc. (TBPH)  
$9.49 0.05 (0.52%) as of 4:30 Wed 5/8


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 63,980,000
Market Cap: 607.17(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $8.22 - $11.59
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 18.6
Insider 6 Months    : 18.6
Insider 3/6 Months : 37.7
Guru Rank Number :  245
Guru Rank Value     : 4.8
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 1,499,124 1,499,124 1,499,124 1,499,124
Total Buy Value $13,117,335 $13,117,335 $13,117,335 $13,117,335
Total People Bought 1 1 1 1
Total Buy Transactions 1 1 1 1
Total Shares Sold 1,254 5,114 22,963 172,089
Total Sell Value $10,922 $50,468 $231,475 $1,835,193
Total People Sold 1 2 2 4
Total Sell Transactions 1 3 11 21
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 530
  Page 12 of 22  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Worboys Philip D SVP, Translational Science   •       –      –    2019-02-05 4 A $0.00 $0 D/D 112,250 274,630     -
   Haumann Brett K SVP Clin Dev & Chief Med Ofc   •       –      –    2019-02-05 4 A $0.00 $0 D/D 112,250 247,161     -
   Pitzer Kenneth R SVP, Prod Strat & Comm Plng   •       –      –    2019-02-05 4 A $0.00 $0 D/D 112,250 270,324     -
   Hegde Sharathchandra S SVP, Research   •       –      –    2019-02-05 4 A $0.00 $0 D/D 112,250 277,247     -
   Pasqualone Frank SVP, Chief Comm Ops Officer   •       –      –    2019-02-05 4 A $0.00 $0 D/D 112,250 328,590     -
   Winningham Rick E Chief Executive Officer   •       •      –    2019-02-05 4 A $0.00 $0 D/D 317,000 1,112,939     -
   Shafer Bradford J EVP, Gen. Counsel, Secretary   •       –      –    2019-02-05 4 A $0.00 $0 D/D 112,250 189,244     -
   Whitesides George M Director   –       •      –    2019-01-02 4 GD $0.00 $0 I/I 21,012 27,650     -
   Worboys Philip D SVP, Translational Science   •       –      –    2018-11-20 4 D $24.79 $108,407 D/D (4,373) 162,380     -
   Winningham Rick E Chief Executive Officer   •       •      –    2018-11-20 4 D $24.79 $385,658 D/D (15,557) 795,939     -
   Hegde Sharathchandra S SVP, Research   •       –      –    2018-11-20 4 D $24.79 $100,722 D/D (4,063) 164,997     -
   Pitzer Kenneth R SVP, Prod Strat & Comm Plng   •       –      –    2018-11-20 4 D $24.79 $96,879 D/D (3,908) 158,074     -
   Gala Renee D SVP, Chief Financial Officer   •       –      –    2018-11-20 4 D $24.79 $166,019 D/D (6,697) 157,657     -
   Shafer Bradford J EVP, Gen. Counsel, Secretary   •       –      –    2018-11-20 4 D $24.79 $173,679 D/D (7,006) 76,994     -
   Haumann Brett K SVP Clin Dev & Chief Med Ofc   •       –      –    2018-11-20 4 D $24.79 $182,653 D/D (7,368) 134,911     -
   Pasqualone Frank SVP, Chief Comm Ops Officer   •       –      –    2018-11-20 4 D $24.79 $142,171 D/D (5,735) 216,340     -
   Worboys Philip D SVP, Translational Science   •       –      –    2018-09-12 4 S $28.50 $182,201 D/D (6,393) 166,753     -
   Shafer Bradford J EVP, Gen. Counsel, Secretary   •       –      –    2018-08-27 4 S $27.71 $197,282 D/D (7,119) 84,000     -
   Worboys Philip D SVP, Translational Science   •       –      –    2018-08-20 4 D $26.95 $148,441 D/D (5,508) 173,146     -
   Hegde Sharathchandra S SVP, Research   •       –      –    2018-08-20 4 D $26.95 $140,086 D/D (5,198) 169,060     -
   Haumann Brett K SVP Clin Dev & Chief Med Ofc   •       –      –    2018-08-20 4 D $26.95 $180,107 D/D (6,683) 142,279     -
   Gala Renee D SVP, Chief Financial Officer   •       –      –    2018-08-20 4 D $26.95 $180,430 D/D (6,695) 164,354     -
   Pitzer Kenneth R SVP, Prod Strat & Comm Plng   •       –      –    2018-08-20 4 D $26.95 $135,909 D/D (5,043) 161,982     -
   Winningham Rick E Chief Executive Officer   •       •      –    2018-08-20 4 D $26.95 $419,261 D/D (15,557) 904,063     -
   Pasqualone Frank SVP, Chief Comm Ops Officer   •       –      –    2018-08-20 4 D $26.95 $154,558 D/D (5,735) 222,075     -
  530 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 12 of 22
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us